Dedicated male abuse survivors line faces closure
The only support service in the country for male sexual abuse victims could be forced to close.
The National Male Survivor Helpline (NMSH) is funded entirely by the government but the Ministry of Justice (MOJ) is to end the £250,000-a-year it has received since 2016.
Service users have said the NMSH, which is operated by Safeline, has been a "lifeline" for many victims of abuse.
The MoJ said its Rape and Sexual Abuse Support Line (RSASL) was available to offer free, confidential help to all survivors aged 16 and over.
A person who used the service from the North West told the BBC they feared male victims would be less likely to use RSASL because all the phonelines were staffed by women only.
"I was abused by a female, the last person I want to speak to about that experience is a woman," he said.
"It is very important that the user can choose the gender of the person they speak to."
The client said he was abused between the ages of eight and 18 and suffered Post Traumatic Stress Disorder (PTSD) as a result.
"PTSD is cumulative, so every time something happens I get triggered, it gets worse," he said.
"I would see someone the same build as the person who abused me and it would trigger me, it got to the point where I was hardly leaving the house."
He said he spent many years trying to get help before he found Safeline's NMSH.
"I tried everything, I self-referred through the NHS and it was a 48-week wait," he said.
"I was given cognitive behavioural therapy and sent to group sessions, but this isn't something you can talk about in a group of strangers."
He said he came across NMSH while researching treatment options and was amazed how quickly it was able to help.
He said "within a matter of weeks" he had been referred for therapy and went on to receive frequent counselling sessions.
"It was just totally different, they completely understood. I wasn't expecting much given my history with other services, and it didn't cost me a penny.
"£250,000 is nothing when you consider what they are doing for people. I'm amazed they managed to help me so much on a tiny budget."
In the last year, the helpline has supported 2,000 men across England and Wales. Sixteen per cent of those were based in the North West, the second highest volume of users after London (18%).
Liz Harrison, Head of National Helpline and Online Services at Safeline, says there will be "tragic consequences" if the NMSH is forced to close.
"Male survivors will go unsupported and lives will be lost," she said.
Ms Harrison said the cuts came after the helpline saw an increase in young men and boys coming forward.
"If you can encourage survivors to seek support as soon as they can it helps to reduce the long term impacts of abuse," she said.
The MoJ said its gender-neutral 24/7 rape crisis line was a suitable alternative to Safeline.
Ms Harrison echoed survivors' concerns about it being staffed only by women.
"The way men and women talk about the abuse they've experienced is completely different," she said.
"Women don't tend to talk about the actual abuse itself whereas men will talk very matter-of-factly about it, which means they can be quite graphic.
"This can lead to them being turned away from the service or even banned."
John, not his real name, is based in Greater Manchester and has worked for the service for nine years.
He said he did not know what to expect when his team was called into a meeting in the middle of December, but that the service being closed was "the worst possible" outcome.
"I went through different phases or being sad, angry, confused that something like this could be taken away," he said.
"I'm surprised by how much I consider it to be part of my identity, it's never felt like a job to me.
"The idea that we spent eight years developing the service to this point for it to be taken away so swiftly just doesn't feel right. We've worked so hard to get it to this point."
John said he was worried the knowledge the team had built over the last nine years would be lost if the service was forced to close.
"We built the service up from scratch so everyone is so knowledgeable about male survivors," he said.
"There is nowhere for us to take that knowledge, the government service won't employ men so we can't even share it with them.
"It just feels like we are being forced to take steps back when we feel like we can and should be moving forward.
"The helplessness of having a service taken out of our hands when we know there is a valid reason we are doing it. It just feels wrong."
The client said he was worried for people who would not be able to access the help he had if the service closed.
"If people can't get help to deal with it they just put it in box in their mind where it just sits and rots. Then they spend the rest of their lives wondering why they feel the way they do, why they need to drink so much or why they take drugs," he said.
"This is a situation that affects possibly millions of men, there are so many people suffering.
"Imagine how many males are going through the same as me who now won't be able to get the help I was given."
The MoJ said it "recognises the vital role that organisations like Safeline play in supporting victims of sexual abuse".
"This government inherited a criminal justice system under immense pressure and must make difficult decisions to ensure we can deliver the justice victims deserve," an MoJ spokesperson said.
But the client said men "get so few opportunities for help", he could not understand why the government would take the service away.
"Safeline is my lifeline," he said.
"It just makes you think, society still doesn't care about men who have been abused.
"Without the specialist help and support I have had from the helpline over the past three years and just knowing they were there for me at the end of the phone, I might not have survived."
If you have been affected by any of the issues raised in this story, information and support can be found at the BBC's Action Line.
Read more stories from Cheshire, Lancashire, Greater Manchester and Merseyside on the BBC, watch BBC North West Tonight on BBC iPlayer and follow BBC North West on X.
National Male Survivor Helpline
Ministry of Justice
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
36 minutes ago
- Fox News
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. "The time is now to address the mental health crisis." Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "There is a huge downside in terms of unregulated recreational uses." "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reporting.


Health Line
2 days ago
- Health Line
What Are the Complications and Long-Term Risks of Meningitis
Meningococcal meningitis can lead to serious complications, such as hearing loss, scarring, or even amputation. Getting treatment early can prevent these outcomes. Meningitis is a condition characterized by swelling of the lining of the brain and spinal cord. It can be caused by viruses, bacteria, or fungi. Meningococcal meningitis occurs when the bacterium Neisseria meningitidis infects the meninges (tissues around the brain and spinal cord). Neisseria meningitidis can also infect the bloodstream. Meningococcal meningitis and bloodstream infections are two common types of meningococcal disease. An infection of the meninges can cause a dangerous buildup of pressure on the brain. Symptoms of infection may include: headache stiff neck confusion sensitivity to light high fever nausea skin rash vomiting Main complications of meningitis Meningococcal disease is fatal in about 10 to 15 people out of every 100 receiving a diagnosis, according to the Centers for Disease Control and Prevention (CDC). The disease may lead to long-term complications in about 20% of those with the condition. Among the possible complications of meningococcal disease are: chronic pain scarring amputation hearing impairment vision impairment motor function impairment post-infection inflammatory syndromes arthritis post-traumatic stress disorder (PTSD) anxiety depression Some complications of meningococcal disease that require immediate medical attention are: septic shock seizures purpura fulminans (skin rash and possible organ failure) hydrocephalus (fluid buildup on the brain) cerebral venous sinus thrombosis (stroke) Waterhouse-Friderichsen syndrome (bleeding into the adrenal glands) subdural empyema (pus between layers of the brain's protective tissue) Bacteremia and septicemia One type of meningococcal disease is an infection of the tissues around the brain and spinal cord (meningococcal meningitis). Neisseria meningitidis can also infect the bloodstream, resulting in bacteremia or septicemia. Meningococcal septicemia is a dangerous form of bloodstream infection. The bacteria multiply and release toxins that can damage blood vessel linings. Bleeding into the skin or organs may occur. A characteristic dark purple rash may develop in the later stages. Other symptoms may include: fatigue vomiting cold hands and feet chills diarrhea rapid breathing severe aches or pains in the muscles, joints, chest, or belly. This form of infection also requires immediate care and can cause some of the most serious complications of meningococcal disease, such as: necrosis (skin death) hearing loss deafness seizures amputation skin scarring impaired blood flow to the organs heart failure Diagnosis and treatment Diagnosing meningococcal disease can be a challenge because early symptoms look like other conditions. When a doctor suspects meningococcal disease, they can test for the presence of bacteria in cerebrospinal fluid or blood. Getting a sample of spinal fluid requires a lumbar puncture procedure. Antibiotics are the mainstay of treatment. Doctors typically start antibiotic treatment as soon as they suspect meningococcal disease to reduce the risk of serious complications. In some cases, someone with meningococcal disease will require hospitalization. Some types of care they might receive include: intensive care unit (ICU) admission and medications to help maintain a stable blood pressure, especially if it drops too low due to severe infection intravenous (IV) fluids and rehydration breathing and airway support blood transfusions wound and skin care How common are meningitis outbreaks? According to the CDC, there were 438 confirmed and probable cases of meningococcal disease in the United States in 2023. The recent rise in cases has been mostly linked to the serogroup Y strain of Neisseria meningitidis, one of several strains that can cause meningococcal disease. Serogroup Y has been spreading more frequently in recent years, contributing to localized outbreaks. Some groups are more at risk than others. Infants, teens, and young adults tend to have higher rates of developing an infection, as do people with certain medical conditions or those living in close quarters like college dorms or military barracks. Outbreaks also tend to occur in communities with lower vaccination rates or limited access to preventive care. That's why it's so important to recognize the signs, respond quickly to symptoms, and stay up to date with recommended vaccines, especially for people at a higher risk. Vaccines are available that help protect against different types of meningococcal disease, including the strains most often linked to outbreaks, such as serogroups A, C, W, Y, and B.
Yahoo
2 days ago
- Yahoo
Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers include new pipeline products and psychedelic therapeutics. Discover market insights, competitor analysis, and strategic opportunities in the 7MM market. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder: Opportunity Assessment and Forecast" report has been added to report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments. The PTSD market across the 7MM was valued at $1.2 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 15.8%, reaching $5.4 billion by 2034. A key driver of growth will be the launch of eight late-stage pipeline products, including the first psychedelic therapeutics for Scope Overview of Post-Traumatic Stress Disorder (PTSD), including epidemiology, symptoms, diagnosis, and disease management. Annualized PTSD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PTSD market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PTSD. The most promising candidates in late-stage development are profiled. Analysis of the current and future market competition in the 7MM PTSD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the 7MM PTSD therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the PTSD therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Company Coverage: GSK Eli Lilly and Co Otsuka Pharmaceutical Co Ltd Pfizer Seelos Therapeutics Ananda Scientific Lykos Therapeutics Idorsia Pharmaceutical Compass Pathways Transcend Therapeutics Neuphoria Therapeutics Key Topics Covered: 1. Preface2. Executive Summary3. Disease Overview3.1. Overview of PTSD3.2. Pathophysiology of PTSD3.3. Classification of PTSD3.4. PTSD SWOT Analysis4. Epidemiology4.1. 12-Month Total Prevalent Cases of PTSD, Men and Women, Ages ? 18 Years, 2024?344.2. Age-Specific 12-Month Total Prevalent Cases of PTSD, Men and Women, 20244.3. Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ?18 Years, 20244.4. 12-Month Total Prevalent Cases of PTSD by Disease Status, Men and Women, Ages ?18 Years, 20244.5. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD4.6. Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Disease Status4.7. Sources Used to Forecast the 12Month Total Prevalent Cases of PTSD by Military Status4.8. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD4.9. Sources and Methodology - 12-Month Total Prevalent Cases of PTSD by Disease Status5. Current Treatment Options5.1. Treatment Paradigm5.2. Current Treatment Options5.3. Product Profile: Pfizer's Zoloft/Besitran/Lustral (sertraline)5.4. Product Profile: GSK's Paxil/Deroxat/Seroxat/Aropax (paroxetine)5.5. Product Profile: Eli Lilly's Prozac (fluoxetine)5.6. Product Profile: Pfizer's Effexor XR/Effexor/Effexor XL/Vandral (venlafaxine)5.7. Product Profile: Pfizer's Minipress/Hypovase (prazosin)5.8. Patient Flow: PTSD in 2024 Across 7MM6. Unmet Needs and Opportunities6.1. Unmet Needs in PTSD6.2. New Therapeutic Options with Improved Efficacy6.3. Increase Access to Psychotherapy6.4. Treatment Options with Improved Side-Effect Profiles6.5. More consistent diagnostic and treatment guidelines7. R&D Strategies7.1. Trends in Clinical Trial Design in PTSD7.2. Regulatory Challenges for Psychedelic Treatments7.3. Timeline of Regulatory Challenges for Lykos Therapeutics7.4. Trends in Deal-Making in PTSD8. Pipeline Assessment8.1. PTSD Pipeline Overview8.2. Late-Stage Pipeline Agents for PTSD8.3. Product Profile: Otsuka Pharmaceutical's Rexulti (brexpiprazole)8.4. Product Profile: Neuphoria Therapeutics' BNC-2108.5. Product Profile: Idorsia Pharmaceutical's Quviviq (daridorexant)8.6. Product Profile: Ananda Scientific's Nantheia ATL5 (cannabidiol)8.7. Product Profile: Transcend Therapeutics' TSND-201 (methylone)8.8. Product Profile: Lykos Therapeutics' midomafetamine hydrochloride8.9. Product Profile: Seelos Therapeutics' Ereska (ketamine hydrochloride)8.10. Product Profile: Compass Pathways' COMP360 (psilocybin)8.11. PTSD: Clinical Trials (Phase II/III) Overview9. Market Outlook9.1. PTSD Market Forecast9.2. Market Drivers and BarriersFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data